Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
eqs_en 
0 06.12.22
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
eqs_en 
0 22.11.22
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
eqs_en 
0 16.11.22
Kinarus Therapeutics Provides Strategic Update
Kinarus Therapeutics Provides Strategic Update
Kinarus Therapeutics Provides Strategic Update
eqs_en 
0 04.11.22
Kinarus Therapeutics Announces Discontinuation of the Phase 2 KINETIC Study of KIN001 in Hospitalized COVID-19 Patients Following a Prespecified Interim Analysis of Efficacy and Safety
Kinarus Therapeutics Announces Discontinuation of the Phase 2 KINETIC Study of KIN001 in Hospitalized COVID-19 Patients Following a Prespecified Interim Analysis of Efficacy and Safety
Kinarus Therapeutics Announces Discontinuation of the Phase 2 KINETIC Study of KIN001 in Hospitalized COVID-19 Patients Following a Prespecified Interim Analysis of Efficacy and Safety
eqs_en 
0 30.09.22
Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update
Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update
Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update
eqs_en 
0 31.08.22
Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in COVID-19 outpatients
Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in COVID-19 outpatients
Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in COVID-19 outpatients
eqs_en 
0 29.08.22
Edison Investment Research Limited: Kinarus Therapeutics (KNRS): Initiation - A unique combination targeting unmet needs
Edison Investment Research Limited: Kinarus Therapeutics (KNRS): Initiation - A unique combination targeting unmet needs
Edison Investment Research Limited: Kinarus Therapeutics (KNRS): Initiation - A unique combination targeting unmet needs
eqs_en 
0 25.08.22
Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19
Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19
Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19
eqs_en 
0 22.08.22
Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville
Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville
Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville
eqs_en 
0 22.08.22
Kinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related Macular Degeneration and potential advantages of KIN001
Kinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related Macular Degeneration and potential advantages of KIN001
Kinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related Macular Degeneration and potential advantages of KIN001
eqs_en 
0 24.06.22